EyePoint, Inc. (EYPT) News
Track canonical SquawkNews coverage tagged to EYPT, EyePoint, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
EyePoint grants inducement awards under Nasdaq Rule 5635(c)(4)
EyePoint Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) for EYPT.
REGULATION | Aug 14, 2026, 08:32 PM UTC
L
EYPT - EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EYPT - EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EARNINGS | Aug 05, 2026, 11:01 AM UTC
H
EyePoint Completes Enrollment
EyePoint completes phase 3 trials
EQUITY | Jul 30, 2026, 11:00 AM UTC
L
EYPT Eyepoint - enters settlement agreement with DOJ, oig-hhs, and dha on July 17, 2026 - SEC filing
EYPT Eyepoint - enters settlement agreement with DOJ, oig-hhs, and dha on July 17, 2026 - SEC filing
REGULATION | Jul 17, 2026, 08:07 PM UTC
L
EYPT U.S. Department of Justice - Eyepoint Pharmaceuticals to Pay $4.6M to Resolve False Claims Act Allegations
EYPT U.S. Department of Justice - Eyepoint Pharmaceuticals to Pay $4.6M to Resolve False Claims Act Allegations
EQUITY | Jul 17, 2026, 02:35 PM UTC
L
EYPT Initiated Buy and $40 PT @ Stifel
EYPT Initiated Buy and $40 PT @ Stifel
EQUITY | Jul 16, 2026, 11:10 AM UTC
L
EYPT Initiate with a Buy, $40 PT @ Stifel
EYPT Initiate with a Buy, $40 PT @ Stifel
EQUITY | Jul 15, 2026, 08:08 PM UTC
L
Chardan Capital Maintains Buy on EyePoint, Raises Price Target to $65
Chardan Capital analyst Andreas Argyrides maintains EyePoint (NASDAQ: EYPT ) with a Buy and raises the price target from $29 to $65.
EQUITY | Jul 01, 2026, 12:52 PM UTC